Back to News
May 5, 2026 4:01 PM

These Analysts Revise Their Forecasts On Vertex Pharmaceuticals After Q1 Earnings

Vertex Pharmaceuticals Inc (NASDAQ:VRTX) reported mixed financial results for the first quarter after the market close on Monday.

Vertex reported first-quarter revenue of $2.99 billion, missing analyst estimates of $3.03 billion, according to Benzinga Pro. The company posted first-quarter adjusted earnings of $4.47 per share, beating estimates of $4.31 per share.

"CASGEVY and JOURNAVX delivered more than 25 percent of our growth this quarter, underscoring the strength of the increasingly diversified revenue base. As we execute across the commercial portfolio and pipeline and build our fourth franchise in nephrology, Vertex is poised to continue to deliver for patients and create long-term value," said ...